CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis

Jennifer L. Taylor-Cousar*, Paul D. Robinson, Michal Shteinberg, Damian G. Downey

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

Following discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989 and subsequent elucidation of the varied CFTR protein abnormalities that result, a new era of cystic fibrosis management has emerged-one in which scientific principles translated from the bench to the bedside have enabled us to potentially treat the basic defect in the majority of children and adults with cystic fibrosis, with a resultant burgeoning adult cystic fibrosis population. However, the long-term effects of these therapies on the multiple manifestations of cystic fibrosis are still under investigation. Understanding the effects of modulators in populations excluded from clinical trials is also crucial. Furthermore, establishing appropriate disease measures to assess efficacy in the youngest potential trial participants and in those whose post-modulator lung function is in the typical range for people without chronic lung disease is essential for continued drug development. Finally, recognising that a health outcome gap has been created for some people and widened for others who are not eligible for, cannot tolerate, or do not have access to modulators is important.

Original languageEnglish
Pages (from-to)1171-1184
JournalThe Lancet
Volume402
Issue number10408
Early online date09 Sept 2023
DOIs
Publication statusPublished - 30 Sept 2023

Fingerprint

Dive into the research topics of 'CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis'. Together they form a unique fingerprint.

Cite this